PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1st quarter of 2016.
The PCAS Group's consolidated net sales totaled €45.3 million in the 1st quarter of 2016, up by 12.2 % compared to the same period in the previous financial year (+10.2 % at constant exchange rate).
in millions of euros
2016
2015
%
change
2016
At a constant exchange rate
%
change
45.3 | 40.4 | 12.2 % | 44.5 | 10.2 % | |||||
30.2 | 25.7 | 17.5 % | 29.5 | 14.6 % | |||||
15.1 | 14.6 | 2.9 % | 15.0 | 2.4 % |
Net sales at 31 march
Pharmaceutical Synthesis
Fine Specialty Chemicals
Pharmaceutical Synthesis activities in Health generated €30.2 million, up 17.5 % compared to 2015 (+14.6 % at constant exchange rate), particularly sustained by the Exclusive activity.
Net sales of Fine Specialty Chemicals amounted to €15.1 million, up 2.9 % compared to 2015 (+2.4 % at a constant exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals.
The company thus confirms its sales growth targets for 2016 as a whole, excluding growth through acquisition, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals.
NEXT FINANCIAL DISCLOSURE:
Net sales of 1st half 2016, July 19th, 2016
About PCAS
PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.
For more information about PCAS: www.pcas.com
PCAS
NewCap
PCAS
NewCap
Financial Communication & investors relations
Tel. : +33 1 69 79 61 32 Tel. : +33 1 44 71 98 53
www.pcas.com
pcas@newcap.eu
PCAS SA issued this content on 20 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 April 2016 16:13:11 UTC
Original Document: http://www.pcas.com/content/download/4283/70382/version/1/file/PR_PCAS_2016_Q1_sales_ENG.pdf